Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02826694 · ClinicalTrials.gov registry record · NA

North Carolina Newborn Exome Sequencing for Universal Screening

A NA study of Hearing Loss and Metabolism, Inborn Errors, sponsored by University of North Carolina, Chapel Hill.

Completed
Registry status
NA
Development phase
106
Enrollment target
1
Study location

NCT02826694: Completed NA study of Hearing Loss and Metabolism, Inborn Errors, sponsored by University of North Carolina, Chapel Hill.

NCT02826694 is a NA study of Hearing Loss and Metabolism, Inborn Errors that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 106 participants, below the 6,119-participant average among 58 other Hearing Loss trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02826694, a NA study of Hearing Loss and Metabolism, Inborn Errors, has completed, sponsored by University of North Carolina, Chapel Hill.

COMPLETED
Registry status
NA
Development phase
106 participants
Enrollment target
1
Study location

Study Summary

The NC NEXUS research study is exploring the utility of next generation sequencing in newborn screening and parental decision making. The National Institutes of Health (NICHD and NHGRI) are co-funding this study under a single U-19.

Primary Outcome

Analysis of parents' decisions after they complete an on-line decision aid to see if they wish to participate in the study. Options will be yes, no, or undecided.

Interventions

  • GENETIC Well infant, whole exome sequencing
  • GENETIC Diagnosed, whole exome sequencing

Study Locations (1)

North Carolina

  • UNC Hospitals - Chapel Hill

Trial Details

FieldValue
Enrollment Target 106 participants
Start Date 2016-06
Est. Completion 2019-06-30
Phase NA

What the finished NCT02826694 record still lists

NCT02826694 is an interventional study that assigns participants to a tested intervention. The registered 106 participants enrollment target is mid-sized for trials with a published cap, below the 6,119-participant average among 58 other Hearing Loss trials with a reported enrollment target (98% lower).

The record links to 3 conditions, with Hearing Loss appearing as the primary indexed condition, and to 2 interventions - of which Well infant, whole exome sequencing is the first listed.

NCT02826694 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT02826694 about?

NCT02826694 is a clinical study titled "North Carolina Newborn Exome Sequencing for Universal Screening". The NC NEXUS research study is exploring the utility of next generation sequencing in newborn screening and parental decision making. The National Institutes of Health (NICHD and NHGRI) are co-funding this study under a single U-19.

What is the current status of trial NCT02826694?

This trial is currently completed. It is a NA study. The enrollment target is 106 participants. The study started on 2016-06. Estimated completion is 2019-06-30.

What conditions does trial NCT02826694 study?

This clinical trial studies the following conditions: Hearing Loss, Metabolism, Inborn Errors, Hereditary Disease.

What interventions are being tested in trial NCT02826694?

The interventions under investigation include: Well infant, whole exome sequencing (GENETIC), Diagnosed, whole exome sequencing (GENETIC).

Who is sponsoring clinical trial NCT02826694?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02826694 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hearing Loss

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02826694's enrollment target sits among peer trials

106 29th of 58 higher than 30 of 58 other Hearing Loss trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hearing Loss trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03181048 · 106 participants · NA

    Clinical Trial of Concomitant Hip Arthroscopy During PAO

  • NCT04682158 · 106 participants · Phase 2

    Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma

  • NCT04724018 · 106 participants · Phase 1

    Sacituzumab Govitecan Plus EV in Metastatic UC

  • NCT04798274 · 106 participants · NA

    Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02826694, the US trial registry maintained by the National Library of Medicine. NCT02826694 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.